Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer

Table 2 The association between the expression of SRY-related HMG box-2 and clinicopathology of patients with triple-negative breast cancer, n (%)

Clinical data	Cases	SOX2 positive expression rate	χ2	P value
Age (yr)			0.000	0.994
< 50	55	41 (74.55)
≥ 50	63	47 (74.60)
BMI (kg/m2)			0.545	0.460
< 22	60	43 (71.67)
≥ 22	58	45 (77.59)
Karnofsky score (points)			0.574	0.449
< 70	52	37 (71.15)
≥ 70	66	51 (77.27)
Differentiation degree			0.000	0.988
High differentiation	51	38 (74.51)
Medium low differentiation	67	50 (74.63)
Intravascular tumor thrombus			7.689	0.006
Yes	25	24 (96.00)
No	93	64 (68.82)
Tumor size			0.420	0.517
> 5 cm	53	38 (71.70)
≤ 5 cm	65	50 (76.92)
TNM stages			7.180	0.007
III	94	65 (69.15)
IV	24	23 (95.83)
Pathological type			0.049	0.825
Invasive ductal carcinoma	96	72 (75.00)
Other	22	16 (72.73)
Ki-67			0.073	0.787
≤ 14%	37	27 (72.97)
> 14%	81	61 (75.31)
P53			0.741	0.389
Positive	79	57 (72.15)
Negative	39	31 (79.49)

SOX2: SRY-related HMG box-2; BMI: Body mass index; TNM: Tumor-node-metastasis.